Global law firm Ashurst has advised MedinCell – listed on Euronext – a commercial-stage pharmaceutical technology company developing a portfolio of long-acting injectable products in a variety of therapeutic areas, on its €25 million capital raising.
MedinCell announced the success of its Global Offering for a final amount of €25.1 million to French and international investors via a Private Placement, and to French retail investors via the PrimaryBid platform.
The purpose of this fundraising is to contribute to the financing of preclinical and clinical activities, new product formulation activities, expansion and improvement of the laboratory in Montpellier, and research and development of new technologies.
The Ashurst Paris team included in corporate partner François Hellot and associate Agathe Bourdillon and, in London, capital markets partner Stuart Rubin and senior associate Rodrigo Romero Hidalgo.
